Aktuellt
SENASTE
Redeye provides a comment on the announcement of a potential indication expansion made by Initiator Pharma earlier today. We are encouraged to learn that the company’s two clinical assets, pudafensine and IP2018, have both shown significant efficacy in preclinical models for Female Sexual Dysfunction (FSD).
LÄS MER
